Decapeptyl Sustained Release 22.5 mg inj. susp. prol.-rel. (pwdr. + solv.) i.m. amp. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

decapeptyl sustained release 22.5 mg inj. susp. prol.-rel. (pwdr. + solv.) i.m. amp. vial

ipsen sa-nv - triptorelin pamoate 31 mg - eq. triptorelin 22,5 mg - powder and solvent for prolonged-release suspension for injection - 22,5 mg - triptorelin pamoate 31 mg - triptorelin

Jaydess 13.5 mg i.uter. delivery system Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

jaydess 13.5 mg i.uter. delivery system

bayer sa-nv - levonorgestrel 13,5 mg; silver colloidal 6,5 mm - intrauterine delivery system - 13,5 mg - levonorgestrel 13.5 mg - plastic iud with progestogen

Basitrin 22.5 mg inj. sol. s.c. pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

basitrin 22.5 mg inj. sol. s.c. pre-filled syr.

basic pharma manufacturing b.v. - methotrexate 22,5 mg/0,6 ml - solution for injection in pre-filled syringe - 22,5 mg - methotrexate 37.5 mg/ml - methotrexate

Movicol 13.8 g or. sol. (pwdr.) sachet Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

movicol 13.8 g or. sol. (pwdr.) sachet

norgine sa-nv - sodium chloride 0,3507 g; sodium hydrogen carbonate 0,1785 g; potassium chloride 0,0466 g; macrogol 13,125 g - powder for oral solution - 13,8 g - macrogol 3350 13125 mg; potassium chloride 46.6 mg; sodium bicarbonate 178.5 mg; sodium chloride 350.7 mg - macrogol, combinations

Movicol Neutral 13.7 g or. sol. (pwdr.) sachet Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

movicol neutral 13.7 g or. sol. (pwdr.) sachet

norgine sa-nv - sodium hydrogen carbonate 0,1786 g; sodium chloride 0,3508 g; potassium chloride 0,0502 g; macrogol 13,125 g - powder for oral solution - 13,7 g - macrogol 3350 13125 mg; potassium chloride 50.2 mg; sodium bicarbonate 178.6 mg; sodium chloride 350.8 mg - macrogol, combinations

Macrogol + Electrolytes AB 13.7 g or. sol. (pwdr.) sachet Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

macrogol + electrolytes ab 13.7 g or. sol. (pwdr.) sachet

aurobindo sa-nv - macrogol 13,125 g; potassium chloride 0,0466 g; sodium hydrogen carbonate 0,1785 g; sodium chloride 0,3507 g - powder for oral solution - 13,7 g - macrogol 3350 13.125 g; sodium chloride 0.351 g; potassium chloride 0.047 g; sodium bicarbonate 0.179 g - macrogol, combinations

Toularynx Guaifenesine 13.33 mg/ml syrup Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

toularynx guaifenesine 13.33 mg/ml syrup

laboratoria qualiphar sa-nv - guaifenesin 13,33 mg/ml - syrup - 13,33 mg/ml - guaifenesin 13.33 mg/ml - guaifenesin

HYDROCLEAN HAND SANITIZER- benzalkonium chloride 0.13% gel United States - English - NLM (National Library of Medicine)

hydroclean hand sanitizer- benzalkonium chloride 0.13% gel

telebrands corp - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - benzalkonium chloride 0.13% w/w...........................antiseptic antiseptic cleansing of hands and body to decrease bacteria on skin without soap and water.

LAMOTRIGINE tablet, extended release United States - English - NLM (National Library of Medicine)

lamotrigine tablet, extended release

zydus pharmaceuticals usa inc. - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - lamotrigine extended-release tablets are indicated as adjunctive therapy for primary generalized tonic-clonic (pgtc) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. lamotrigine extended-release tablets are indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (aed). safety and effectiveness of lamotrigine extended-release have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from 2 or more concomitant aeds. safety and effectiveness of lamotrigine extended-release for use in patients younger than 13 years have not been established. lamotrigine extended-release is contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients [see boxed warning, warnings and precautions (5.1